Sebold Capital Management Inc. Sells 104 Shares of The Cigna Group (NYSE:CI)

Sebold Capital Management Inc. lowered its position in The Cigna Group (NYSE:CI) by 8.2% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 1,169 shares of the health services provider’s stock after selling 104 shares during the period. Sebold Capital Management Inc.’s holdings in The Cigna Group were worth $350,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors also recently made changes to their positions in CI. Bogart Wealth LLC grew its holdings in shares of The Cigna Group by 104.5% in the 3rd quarter. Bogart Wealth LLC now owns 90 shares of the health services provider’s stock valued at $26,000 after buying an additional 46 shares during the period. OFI Invest Asset Management bought a new position in The Cigna Group in the third quarter valued at approximately $26,000. Fortitude Family Office LLC bought a new stake in shares of The Cigna Group during the fourth quarter worth $29,000. Fairfield Bush & CO. bought a new position in The Cigna Group during the 2nd quarter worth about $28,000. Finally, VisionPoint Advisory Group LLC raised its stake in shares of The Cigna Group by 112.2% in the 3rd quarter. VisionPoint Advisory Group LLC now owns 104 shares of the health services provider’s stock valued at $30,000 after purchasing an additional 55 shares during the period. 86.99% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several brokerages have issued reports on CI. Deutsche Bank Aktiengesellschaft upgraded shares of The Cigna Group from a “hold” rating to a “buy” rating and lifted their price target for the company from $355.00 to $370.00 in a research note on Thursday, February 1st. Sanford C. Bernstein raised The Cigna Group from a “market perform” rating to an “outperform” rating and raised their price objective for the company from $330.00 to $372.00 in a research report on Thursday, January 4th. StockNews.com raised The Cigna Group from a “buy” rating to a “strong-buy” rating in a report on Thursday, March 14th. Jefferies Financial Group raised shares of The Cigna Group from a “hold” rating to a “buy” rating and increased their price target for the company from $335.00 to $341.00 in a report on Monday, December 11th. Finally, Royal Bank of Canada raised The Cigna Group from a “sector perform” rating to an “outperform” rating and lifted their target price for the stock from $327.00 to $354.00 in a report on Monday, February 5th. Two equities research analysts have rated the stock with a hold rating, ten have given a buy rating and two have given a strong buy rating to the stock. According to data from MarketBeat, the company currently has an average rating of “Buy” and an average price target of $361.29.

Insiders Place Their Bets

In other news, CEO David Cordani sold 38,065 shares of The Cigna Group stock in a transaction that occurred on Friday, February 9th. The stock was sold at an average price of $335.22, for a total value of $12,760,149.30. Following the sale, the chief executive officer now directly owns 329,321 shares in the company, valued at approximately $110,394,985.62. The sale was disclosed in a filing with the SEC, which is available through this link. In other The Cigna Group news, CEO David Cordani sold 38,065 shares of The Cigna Group stock in a transaction dated Friday, February 9th. The shares were sold at an average price of $335.22, for a total value of $12,760,149.30. Following the completion of the transaction, the chief executive officer now directly owns 329,321 shares of the company’s stock, valued at $110,394,985.62. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, SVP Hoeltzel Mary T. Agoglia sold 4,867 shares of the firm’s stock in a transaction that occurred on Wednesday, February 7th. The shares were sold at an average price of $330.48, for a total transaction of $1,608,446.16. Following the sale, the senior vice president now directly owns 2,102 shares of the company’s stock, valued at approximately $694,668.96. The disclosure for this sale can be found here. Insiders sold a total of 114,144 shares of company stock valued at $39,296,330 over the last 90 days. Insiders own 0.60% of the company’s stock.

The Cigna Group Stock Up 1.6 %

NYSE:CI opened at $363.38 on Thursday. The firm’s 50 day simple moving average is $332.16 and its 200 day simple moving average is $307.08. The company has a debt-to-equity ratio of 0.61, a current ratio of 0.67 and a quick ratio of 0.67. The Cigna Group has a one year low of $240.50 and a one year high of $364.71. The company has a market cap of $106.24 billion, a PE ratio of 20.90, a P/E/G ratio of 1.10 and a beta of 0.55.

The Cigna Group (NYSE:CI) last issued its quarterly earnings data on Friday, February 2nd. The health services provider reported $6.79 EPS for the quarter, topping analysts’ consensus estimates of $6.54 by $0.25. The firm had revenue of $51.15 billion during the quarter, compared to analyst estimates of $48.91 billion. The Cigna Group had a return on equity of 13.59% and a net margin of 2.64%. During the same period in the previous year, the company posted $4.96 EPS. The company’s revenue for the quarter was up 11.8% on a year-over-year basis. On average, research analysts anticipate that The Cigna Group will post 28.36 earnings per share for the current year.

The Cigna Group Increases Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Thursday, March 21st. Investors of record on Wednesday, March 6th were paid a dividend of $1.40 per share. This is a positive change from The Cigna Group’s previous quarterly dividend of $1.23. The ex-dividend date was Tuesday, March 5th. This represents a $5.60 annualized dividend and a yield of 1.54%. The Cigna Group’s dividend payout ratio (DPR) is currently 32.20%.

About The Cigna Group

The Cigna Group, together with its subsidiaries, provides insurance and related products and services in the United States. Its Evernorth Health Services segment provides a range of coordinated and point solution health services, including pharmacy benefits, home delivery pharmacy, specialty pharmacy, distribution, and care delivery and management solutions to health plans, employers, government organizations, and health care providers.